The prognostic value of a positive ctDNA test in urothelial cancer intensifies throughout the treatment journey. Failure to clear ctDNA after neoadjuvant therapy and then surgery is associated with a dramatically increasing hazard ratio for death, signaling profound treatment failure.

The INVIGOR-11 trial data should be applied carefully. A positive ctDNA result post-surgery indicates when to *initiate* adjuvant immunotherapy. However, if a patient on neoadjuvant therapy becomes ctDNA-negative, this signals treatment efficacy and is a reason to *continue* the planned course, not a justification for stopping it early.

Circulating tumor DNA (ctDNA) is a powerful tool in bladder cancer. A positive result post-surgery is a strong indicator for initiating adjuvant therapy. However, a negative result does not guarantee a cure, as a notable percentage of these patients still relapse, making clinicians cautious about withholding treatment based on a single negative test.

While trials like IMvigor011 show ctDNA can guide adjuvant immunotherapy after surgery, this data may not apply to the new standard of care. With neoadjuvant EV/pembrolizumab becoming prevalent, the prognostic and predictive value of post-operative ctDNA is now unknown, requiring new prospective studies.

Circulating tumor DNA (ctDNA) identifies post-surgery patients at high risk of relapse. By targeting adjuvant immunotherapy to only this ctDNA-positive group, previously negative clinical trials demonstrate a significant survival benefit. This approach spares low-risk, ctDNA-negative patients from unnecessary treatment and toxicity.

Circulating tumor DNA (ctDNA) is a powerful biomarker for identifying high-risk bladder cancer patients. However, its imperfection presents a new clinical dilemma: with a ~12% relapse rate even in ctDNA-negative patients, clinicians must decide whether to withhold adjuvant therapy and accept that risk, or overtreat the 88% who are likely cured.

Experts find a positive circulating tumor DNA (ctDNA) test more useful for informing a decision to start adjuvant therapy. A negative result is considered less helpful and doesn't provide the same level of reassurance or definitively rule out treatment, as the pivotal clinical trial was designed to address the ctDNA-positive scenario.

In adjuvant bladder cancer trials, ctDNA status is both prognostic and predictive. Patients with positive ctDNA after surgery are at high risk of relapse but benefit from immune checkpoint inhibitors. Conversely, ctDNA-negative patients have a lower risk and derive no benefit, making ctDNA a critical tool to avoid unnecessary, toxic therapy.

A positive ctDNA result post-surgery in an immunotherapy-naive patient warrants starting treatment. Conversely, if a patient received neoadjuvant immunotherapy and remains ctDNA positive after surgery, it signals resistance, making continuation of the same therapy illogical and creating a clinical paradox.